Visceral fat is the fat stored deep around your abdominal organs, and it is more closely tied to heart and metabolic disease than total weight. A tape measure around your waist is a simple home check, and exercise can shrink visceral fat even when the scale barely moves.
Visceral fat is the fat stored deep inside the abdomen, around the abdominal organs, rather than just under the skin. Research using CT and MRI scans shows that it is an independent marker of cardiovascular and metabolic risk, which is why two people with the same weight can have very different health profiles. You cannot see visceral fat directly at home, but your waist measurement is a practical stand-in, and regular exercise can reduce visceral fat even when the scale changes little.
Body fat is not one uniform tissue. Fat just under the skin is called subcutaneous fat. Fat packed around the abdominal organs is called visceral fat (or visceral adipose tissue). A 2019 position statement from the International Atherosclerosis Society and the International Chair on Cardiometabolic Risk, published in The Lancet Diabetes and Endocrinology, summarized 30 years of research:
That link to liver fat is one reason visceral fat comes up so often in conversations about fatty liver disease.
The same position statement noted that while BMI predicts risk well across large populations, there is "considerable variation" in cardiometabolic risk among individuals with the same BMI. Imaging studies have shown that BMI is limited as a tool for identifying the people with excess visceral fat, who represent the highest-risk group.
Where your body stores fat is partly outside your control. The NIDDK notes that genes may influence how much fat you store and where on your body you carry it. NHLBI adds that people whose fat sits mainly around the waist, rather than the hips, face a higher risk of heart disease and type 2 diabetes. NIDDK also lists a large waist size among the risk factors for insulin resistance and prediabetes.
Clinical imaging is not practical for routine checkups, and the 2019 statement acknowledged that measuring fat distribution in everyday practice remains a challenge. The most accessible substitute is waist circumference.
A 2020 consensus statement in Nature Reviews Endocrinology argued that waist circumference should be treated as a "vital sign." Its authors found that waist size adds independent information beyond BMI for predicting illness and death, yet is rarely measured in clinical practice. They also reported that self-measurement agrees well with measurements taken by trained staff.
NHLBI describes a simple method:
| Group | Waist size associated with increased risk (NHLBI) |
|---|---|
| Women | More than 35 inches |
| Men | More than 40 inches |
These cutoffs are a starting point, not a diagnosis. The 2020 consensus noted that waist thresholds still need refinement by age, sex and ethnicity. Another approach, comparing waist to height, is covered in our guide to BMI, waist size and body fat. Measuring the same way each time matters more than which exact landmark you choose; the consensus found that the measurement method had no substantial influence on how well waist size predicted risk.
A 2016 meta-analysis in Obesity Reviews pooled 117 studies with 4,815 participants that measured visceral fat with imaging. Key findings:
The authors concluded that total weight loss "does not necessarily reflect changes" in visceral fat. In practical terms, if you are exercising regularly and your weight is stable, your waist measurement may be a better sign of progress than the scale. The 2020 consensus similarly reported that routine moderate-intensity exercise, diet changes or both can produce clinically relevant reductions in waist size.
Diet-driven weight loss also reduces visceral fat, and in the meta-analysis, changes in weight and visceral fat were strongly correlated after diet interventions. Our TDEE calculator can help you estimate your daily energy needs as a starting point for planning.
GLP-1 medications reduce visceral fat as part of overall fat loss. In an exploratory analysis of the STEP 1 trial, 140 participants had body composition measured with DEXA scans. Over 68 weeks, people on semaglutide had average weight change of -15.0 percent versus -3.6 percent on placebo, with reductions of 19.3 percent in total fat mass and 27.4 percent in regional visceral fat mass. Lean mass also fell by 9.7 percent, although its share of total body weight rose.
That analysis used FDA-approved semaglutide. Compounded GLP-1 medications are not FDA-approved and were not part of that study. Whether any medication is appropriate is a decision for a licensed provider, and dosing is always set by the prescriber.
The research summarized here looked at overall exercise programs and calorie reduction, not targeted abdominal exercises. What reduced visceral fat in those studies was regular exercise and overall fat loss. Core work can still be part of a balanced routine.
Research using CT and MRI identifies visceral fat as an independent risk marker for cardiovascular and metabolic disease, and it often occurs alongside fat in the liver and heart. Waist-centered fat is linked to higher risk of heart disease and type 2 diabetes than fat carried mainly on the hips.
Yes, it is possible. Position statements note that people with the same BMI vary widely in visceral fat and cardiometabolic risk, which is why experts recommend measuring waist size along with BMI rather than relying on weight alone.
Timelines vary by person and approach. The studies here measured change over weeks to months of consistent exercise, dietary change or medication. Tracking your waist periodically, measured the same way each time, shows the trend better than any single reading.
If your waist measurement is above the NHLBI thresholds, or you have a family history of heart disease or diabetes, a licensed provider can check related markers such as blood pressure, blood sugar and lipids and help you build a plan. Start with a tape measure and our BMI calculator to bring a fuller picture to that conversation. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
Resistance training is the single most effective way to protect muscle and bone while losing weight. Here is what the guidelines recommend, what the research shows, and how to begin safely without a gym background.
Read article
Obesity behaves like a chronic condition, and the trial data on stopping GLP-1 medications show why. What long-term management looks like, what a licensed provider monitors, and how to think about maintenance.
Read articleGLP-1 medications copy a hormone your gut already makes. Here is what that hormone does, how the medications change appetite and digestion, and which products are FDA-approved versus compounded.
Read article